A Trial on the Overexpression of Epidermal Growth Factor Receptor and Proliferating Cell Nuclear Antigen in NSCLC of Similar Differentiation

Abstract:

Objective: To explore the expression of EGFR and PCNA in lung squamous cell carcinomas and lung adenocarcinomas, and the relationships between their overexpression and cancer tissue typing or lymphatic metastasis. Method: Detect the expression of EGFR and PCNA in 44 cases of similarly differentiated cancer tissue and 16 cases of normal lung tissue by immunohistochemistry. Result: The expression of EGFR and PCNA in lung cancer tissue was significantly higher than that in normal lung tissue. Meanwhile, no significant difference existed between expression of PCNA and EGFR in lung squamous carcinomas and that in lung adenocarcinomas (P>0.05), nor between lymph node metastatic tissue and negative lymph node metastatic tissue (P>0.05). Conclusion: EGFR and PCNA were involved in the onset and development of lung cancer, and had some correlation with lung cancer. No significant correlations were observed between EGFR or PCNA overexpression and lymph node metastasis.

• Periodical: Advanced Materials Research (Volumes 881-883)
• Pages: 410-413
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.881-883.410
• Online since: January 2014
• Authors: Feng Wu Lin, Chuan Zhang, Kun Peng Cheng, Qiang Zhang, Yan Zhao*
• Keywords: Epidermal Growth Factor Receptor (EGFR), Lung Cancer, Proliferating Cell Nuclear Antigen (PCNA)

References

[1] Xu RB. Basic and clinical research of receptors[M]. Shanghai: Shanghai Science and Technology Press, (1992).

[2] Bravo R, Frank R, Blundell PA, et al. Cylin/PCNA is the auxiliary protein of DNA polymerase-delta [j]. Nature, 1987, 326: 515~517.

DOI: 10.1038/326515a0

[3] Fujinos, Enokibori, Tezuka N, et al. Acomparison of epidermal growht factor receptor levels and other prognostic parameters in no-small cell lung cancer [j]. Eur J Cancer, 1996, 32A (12): 2090~(2074).

DOI: 10.1016/s0959-8049(96)00243-2

[4] Liu GL, Zhang WD, Song YG. The detectation of EGF and EGFR in lung carcinoma tissue[J]. Guangdong Medicine, 1995, 16.

[2] 76~77.

[5] Ishida T, Kaneko S, Akazawz K, et al. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung [J] Cancer Res, 1992, 53: 5000~5003.

DOI: 10.1016/0169-5002(96)84292-9

[6] Kawa T, Suzuki M, Kono S, et al. Proliferating cell nuclear antigen and Ki-67 in lung carcinoma [J]. Cancer, 1994, 74 (9): 2468~2475.

DOI: 10.1002/1097-0142(19941101)74:9<2468::aid-cncr2820740913>3.0.co;2-x

[7] Pirker R, Pereira R, Vov Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012 , 13(1): 33-42.

DOI: 10.1016/s1470-2045(11)70318-7

[8] Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, et al. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008, 61: 553–560.

DOI: 10.1136/jcp.2008.055475

[9] Wang SC, Nakajima Y, Yu YL, Xia W, Chen CT, et al. Tyrosine phosphorylation controls PCNA function through protein stability. 2006, Nat Cell Biol 8: 1359–1368.

DOI: 10.1038/ncb1501

[10] Mascaux C, Wynes MW, Kato Y, et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-a novel antibody for immunohistochemistry or AQUA technology. Clin Cancer Res. 2011 15; 17(24): 7796-7807.

DOI: 10.1158/1078-0432.ccr-11-0209

[11] McMillen E, Ye F, Li G, et al. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer. Exp Lung Res. 2010; 36(9): 531-7.

DOI: 10.3109/01902148.2010.482176